DiBenedetto David J, Wawrzyniak Kelly M, Schatman Michael E, Kulich Ronald J, Finkelman Matthew
Boston PainCare, Waltham, MA, USA,
Department of Diagnostic Sciences, Tufts School of Dental Medicine, Boston, MA, USA.
J Pain Res. 2018 Nov 20;11:2929-2941. doi: 10.2147/JPR.S188795. eCollection 2018.
To evaluate clinical outcomes and health care utilization at 12 months post spinal cord stimulator (SCS) implantation compared with baseline and a matched sample of patients receiving conventional medical management (CMM) for the treatment of low back and lower extremity pain.
A retrospective study of patients with at least 24 months of active treatment at an interdisciplinary community pain center between December 1, 2014 and December 31, 2017. Thirty-two patients receiving implantation of a high-frequency (10 kHz) SCS and 64 patients receiving CMM were identified through propensity matching at a ratio of 2:1.
Data were extracted from medical records, including pain severity, prescribed opioid dose in morphine milligram equivalents, patient perception of disability, and volume of interventional pain procedures and total office visits to the pain center.
Reductions in opioid dose were significantly greater for the SCS group than the CMM group. The 26.2 mg morphine equivalent dose reduction represents a 28% reduction from baseline, with 71.4% of those prescribed opioids in the SCS group reducing their dose at 12 months post-implant. Among those with SCS, there were significant within-group reductions in numerical pain score for low back and lower extremity pain, reducing by 46.2% and 50.9% from baseline, respectively. Change in functional pain score was not significant for either SCS group or CMM. Both groups had significant within-group reduction in disability. Reduction of interventional procedure volume was significant for both groups with a greater reduction observed in the SCS group. Office visit volume reduction was significant for the CMM group, but this was not a significant difference from the SCS group.
Results support the efficacy of 10 kHz SCS for analgesia, reduction of opioid utilization, reduction of interventional pain procedures, and patient perception of disability.
评估脊髓刺激器(SCS)植入术后12个月的临床疗效和医疗资源利用情况,并与基线水平以及接受传统药物治疗(CMM)以治疗腰背部和下肢疼痛的匹配患者样本进行比较。
对2014年12月1日至2017年12月31日期间在一个跨学科社区疼痛中心接受至少24个月积极治疗的患者进行回顾性研究。通过倾向匹配以2:1的比例确定了32例接受高频(10 kHz)SCS植入的患者和64例接受CMM治疗的患者。
从医疗记录中提取数据,包括疼痛严重程度、以吗啡毫克当量计的处方阿片类药物剂量、患者对残疾的感知以及介入性疼痛治疗程序的数量和到疼痛中心的总门诊次数。
SCS组的阿片类药物剂量减少幅度明显大于CMM组。26.2毫克吗啡当量的剂量减少代表较基线水平降低了28%,SCS组中71.4%接受阿片类药物处方的患者在植入后12个月减少了剂量。在接受SCS治疗的患者中,腰背部和下肢疼痛的数字疼痛评分在组内有显著降低,分别较基线水平降低了46.2%和50.9%。SCS组和CMM组的功能性疼痛评分变化均不显著。两组在组内残疾程度均有显著降低。两组的介入性治疗程序数量均显著减少,SCS组的减少幅度更大。CMM组的门诊次数减少显著,但与SCS组相比无显著差异。
结果支持10 kHz SCS在镇痛、减少阿片类药物使用、减少介入性疼痛治疗程序以及患者对残疾的感知方面的疗效。